Relapsed Neuroblastoma Clinical Trial
Official title:
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
This expanded access is the best available therapy/compassionate use designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.
Primary Objective is to provide access to therapy with 131I-MIBG for patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma. Secondary Objectives are to (1) assess disease response to 131I-MIBG therapy for patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma; (2) gain more information about the toxicities of 131I-MIBG therapy; and (3) assess improvement of symptoms, including pain and fatigue, for patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are receiving 131I-MIBG therapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04211675 -
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05400603 -
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma
|
Phase 1 | |
| Recruiting |
NCT05650749 -
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma
|
Phase 1 | |
| Withdrawn |
NCT03406273 -
Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma
|
N/A | |
| Active, not recruiting |
NCT02282735 -
Parental Decision-Making for Children With Relapsed Neuroblastoma
|
||
| Withdrawn |
NCT03209869 -
Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2
|
Phase 1 | |
| Recruiting |
NCT04049864 -
DNA Vaccination Against Neuroblastoma
|
Early Phase 1 | |
| Suspended |
NCT01850888 -
MIBG for Refractory Neuroblastoma and Pheochromocytoma
|
N/A | |
| Recruiting |
NCT04023331 -
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03635632 -
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
|
Phase 1 | |
| Completed |
NCT01109238 -
A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma
|